Search results for "fabry"

showing 10 items of 171 documents

Genotype–phenotype correlation in a new Fabry-disease-causing mutation

2019

Background: Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by α-galactosidase A deficiency leading to intracellular glycosphingolipid accumulation. FD manifestation is multisystem, and can differ depending on disease-related genetic variants. Currently, more than 700 different FD-causing mutations have been identified in the human GLA gene. We identified a novel mutation in a Lithuanian family with classical manifestations of Fabry disease, revealing severe effects to the cardiovascular systems of heterozygous women. Case presentation: A 49-year-old woman underwent echocardiography due to progressive dyspnea that lasted seven years, reduced physical a…

Probandmedicine.medical_specialtyAbdominal painMedicine (General)α-galactosidase ACase ReportLeft ventricular hypertrophyGastroenterologyclassical manifestationR5-920Internal medicinemedicineGLA geneFabry diseasemedicine.diagnostic_testbusiness.industryCardiac arrhythmiaGeneral MedicineFabry disease ; α-galactosidase A ; GLA gene ; novel mutation ; classical manifestationmedicine.diseaseFabry diseaseHyperintensityMutation (genetic algorithm)<i>GLA</i> geneRenal biopsymedicine.symptomnovel mutationbusiness
researchProduct

Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories : production of human alpha-gala…

2015

This work was supported by ERANET-IB08-007 project from the European Union and its linked national project EUI2008- 03610 to AV. We also appreciate the support from EME2007-08 to NFM from Universitat Autonoma de Barcelona, from Antartide 2010 to MLT and EP, from MIUR Azioni Integrate Italia-Spagna 2010 Prot. IT10LECLM9 to MLT, from MINECO (IT2009-0021) to AV and LT, from AGAUR (2009SGR-108) to AV. AV is also supported by The Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN, Spain), an initiative funded by the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Car…

PseudoalteromonaRecombinant proteinExpression systemsFabry's diseaseHuman alpha-galactosidase AContext (language use)Computational biologyBiologymedicine.disease_causeApplied Microbiology and BiotechnologyMicrobiologyPseudoalteromonas haloplanktisGene expressionEnzyme StabilitymedicineProtein biosynthesisEscherichia coliHumansEscherichia coliGenePseudoalteromonas haloplanktis TAC125Expression systemGeneral Medicinebiology.organism_classificationRecombinant ProteinsPseudoalteromonasMembrane proteinFabry’s diseaseMetabolic Engineeringalpha-GalactosidaseProtein foldingBiotechnologyHuman
researchProduct

Finely tunable laser based on a bulk silicon wafer for gas sensing applications

2016

In this work a very simple continuously tunable laser based on an erbium ring cavity and a silicon wafer is presented. This laser can be tuned with very fine steps, which is a compulsory characteristic for gas sensing applications. Moreover the laser is free of mode hopping within a spectral range sufficiently wide to match one of the ro-vibrational lines of a target molecule. Here the proposed laser reached, at ∼1530 nm, a continuous tuning range of around 950 pm (>100 GHz) before mode hopping occurred, when a silicon wafer of 355 μm thickness was used. Additionally, the laser can be finely tuned with small tuning steps of <12 pm, achieving a resolution of 84.6 pm °C-1 and by using a therm…

Range (particle radiation)Materials sciencePhysics and Astronomy (miscellaneous)Hybrid silicon laserbusiness.industrychemistry.chemical_element02 engineering and technologyLaser01 natural scienceslaw.invention010309 opticsErbiumWavelength020210 optoelectronics & photonicsOpticschemistrylaw0103 physical sciences0202 electrical engineering electronic engineering information engineeringWaferbusinessInstrumentationFabry–Pérot interferometerTunable laserLaser Physics Letters
researchProduct

Pathogenesis and molecular mechanisms of anderson–fabry disease and possible new molecular addressed therapeutic strategies

2021

Anderson–Fabry disease (AFD) is a rare disease with an incidenceof approximately 1:117,000 male births. Lysosomal accumulation of globotriaosylceramide (Gb3) is the element characterizing Fabry disease due to a hereditary deficiency α-galactosidase A (GLA) enzyme. The accumulation of Gb3 causes lysosomal dysfunction that compromises cell signaling pathways. Deposition of sphingolipids occurs in the autonomic nervous system, dorsal root ganglia, kidney epithelial cells, vascular system cells, and myocardial cells, resulting in organ failure. This manuscript will review the molecular pathogenetic pathways involved in Anderson–Fabry disease and in its organ damage. Some studies reported that i…

ReviewConstriction Pathologicendothelial dysfunctionPathogenesisMicechemistry.chemical_compoundKCa3.1 activitypodocyturiaProtein IsoformsEndothelial dysfunctionBiology (General)SpectroscopyglobotriaosylceramideGlobosidesMicrogliabiologyTOR Serine-Threonine KinasesTrihexosylceramidesmiR-26a-5pGeneral MedicineMitochondriaComputer Science ApplicationsCell biologymiR-152-5pChemistrymedicine.anatomical_structureCerebrovascular CirculationAnderson–Fabry disease Endothelial dysfunction Globotriaosylceramide KCa3.1 activity MiR-1307-5p MiR-152-5p MiR-21-5p MiR-26a-5p Podocyturia Valvular dysfunctionmiR-21-5pSignal TransductionQH301-705.5GlobotriaosylceramideCatalysisInorganic ChemistryAutophagymedicineAnimalsHumansEnzyme Replacement TherapyPhysical and Theoretical ChemistryMolecular BiologyMechanistic target of rapamycinQD1-999PI3K/AKT/mTOR pathwaySphingolipidsAnderson–Fabry diseasebusiness.industryMicrocirculationOrganic ChemistryEndothelial Cellsmedicine.diseaseFabry diseaseSphingolipidMicroRNAschemistrymiR-1307-5palpha-Galactosidasebiology.proteinFabry DiseaseGlycolipidsvalvular dysfunctionLysosomesbusiness
researchProduct

Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease

2021

Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by lysosomal accumulation of glycosphingolipids in a wide variety of cytotypes, including endothelial cells (ECs). FD patients experience a significantly reduced life expectancy compared to the general population

SenescencePremature agingAdultMalesenescenceAdolescentPopulationsmall extracellular vesiclesUmbilical veinArticleAndrologyExtracellular VesiclesYoung AdultHUVECIn vivosmall extracellular vesicleHuman Umbilical Vein Endothelial CellsmiR-126-3pMedicineHumanseducationlcsh:QH301-705.5Cellular SenescenceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studySphingolipidsFabry diseasemicroRNAbusiness.industryagingAging PrematureGeneral MedicineMiddle Agedmedicine.diseaseFabry diseaseendothelial cellsMicroRNAslcsh:Biology (General)endothelial cellBiomarker (medicine)NanoparticlesFemaleGlycolipidsbusinessReactive Oxygen SpeciesEx vivoBiomarkersCells
researchProduct

Misdiagnosis of familial Mediterranean fever in patients with Anderson-Fabry disease

2013

Fabry disease (FD) is an underdiagnosed pathology due to its symptomatology that overlaps with various systemic and rheumatic disorders, including familial Mediterranean fever (FMF). We examined the Mediterranean fever (MEFV) and α-galactosidase A (GLA) genes, whose mutations are responsible for FMF and FD, respectively, in 42 unrelated patients diagnosed with FMF, which revealed significant ambiguity regarding some of the symptoms which are also present in FD. The objective of this study was to determine the spectrum of mutations present in these genes, in order to identify cases of mistaken diagnosis of FMF and/or missed diagnosis of FD. Ten out of 42 patients had one mutation in homozyg…

Settore MED/04 - Patologia GeneraleFabbry Diseasefamilial Mediterranean feverMEFVAnderson-Fabry diseaseMEFV; familial Mediterranean fever; Anderson-Fabry diseaseMediterranean Fever Genetic diseases
researchProduct

Estensione della definizione di Malattia di Fabry in base ai dati ottenuti dallo studio dell'attività enzimatica e degli aplotipi genetici

2011

Settore MED/09 - Medicina InternaMalattia di Fabryattività enzimaticaaplotipi genetici
researchProduct

La Malattia Di Anderson –Fabry

2008

Settore MED/35 - Malattie Cutanee E VenereeMalattia Di Anderson –Fabry
researchProduct

Terapia Enzimatica Sostitutiva Della Malattia Di Fabry:Due Anni Di Esperienza

2004

Settore MED/35 - Malattie Cutanee E VenereeMalattia Di Fabry
researchProduct

Spectrochemical Rubidium-Strontium Method for Geological Age Determination

1960

The age values of lepidolites from South Africa and from Varutrask as well as that of a microcline from Varutrask have been determined and are discussed in connection with determination according to the potassium-argon method, applied to the same materials A method is suggested which allows the spectrochemical determination of Rb and Sr with sufficient accuracy. The isotopic composition is determined by means of a Fabry-Perot etalon and hollow-cathode excitation, investigating the hyper-fine structure of the Sr line at 4078 A.

StrontiumMicrocline010401 analytical chemistryAnalytical chemistrychemistry.chemical_elementMineralogyengineering.material01 natural sciencesIsotopic composition0104 chemical sciencesRubidium010309 opticschemistryAge values0103 physical sciencesengineeringInstrumentationSpectroscopyFabry–Pérot interferometerApplied Spectroscopy
researchProduct